Make an Inquiry
Accelerating Periodic Fever Syndrome Drug Development

Periodic fever syndrome (autoinflammatory syndrome) presents complex therapeutic challenges due to its multifaceted pathogenesis and unmet clinical needs. Protheragen is a specialized partner in preclinical drug development for Periodic fever syndrome, offering a comprehensive suite of services spanning target validation, lead optimization, and IND-enabling studies. Leveraging deep scientific expertise and advanced technological platforms, Protheragen delivers robust preclinical data to support the progression of novel therapeutics in this challenging field. Our integrated approach ensures rigorous evaluation of candidate compounds, with a strong emphasis on mechanistic insight and translational relevance. Protheragen maintains strict adherence to regulatory standards, providing clients with confidence in data quality and process integrity throughout the preclinical pipeline. With a commitment to scientific excellence and innovation, Protheragen accelerates the development of transformative therapies for Periodic fever syndrome, driving progress from discovery to clinical readiness.

What is Periodic Fever SyndromeTargets for Periodic Fever SyndromeDrug Discovery and Development ServicesWhy Choose Us

What is Periodic Fever Syndrome

Periodic Fever Syndromes (PFS), also known as autoinflammatory syndromes, are a group of rare disorders characterized by recurrent episodes of fever and systemic inflammation without evidence of infection or autoantibody production. These syndromes are primarily caused by genetic mutations affecting proteins that regulate the innate immune response, such as MEFV, NLRP3, TNFRSF1A, and MVK. The resulting dysregulation leads to inappropriate activation of the inflammasome and excessive production of pro-inflammatory cytokines, particularly interleukin-1 (IL-1), driving the inflammatory episodes observed in these conditions. Clinically, PFS presents with recurrent fevers accompanied by symptoms such as rash, serositis, arthralgia, abdominal pain, and, in some cases, complications like amyloidosis. Diagnosis relies on clinical criteria, family history, and increasingly on genetic testing to identify pathogenic mutations, while laboratory findings typically show elevated acute phase reactants during attacks. Exclusion of infectious, autoimmune, and neoplastic causes is essential. Treatment is syndrome-specific: colchicine is the mainstay for Familial Mediterranean Fever, while targeted therapies such as canakinumab, rilonacept, and anakinra—agents that inhibit IL-1 signaling—are effective for other syndromes like CAPS, TRAPS, and MKD/HIDS, reducing attack frequency and preventing long-term complications.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
canakinumab (Prop INN; USAN) 914613-48-2
img-64-86-8-colchicine colchicine 64-86-8 C22 H25 N O6 399.437
IL-1 cytokine Trap; interleukin-1 Trap; rilonacept (Rec INN; USAN) 501081-76-1
anakinra (Rec INN; USAN) 143090-92-0

Learn More

Targets for Periodic Fever Syndrome

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Histone deacetylase (nonspecified subtype)
interleukin 1 beta IL1B
tumor necrosis factor TNF

Periodic Fever Syndrome (PFS) is driven by dysregulation of innate immune pathways, with central roles played by pro-inflammatory cytokines interleukin 1 beta (IL1B) and tumor necrosis factor (TNF). IL1B is produced as an inactive precursor and activated by caspase-1 within the inflammasome, leading to potent induction of fever and inflammation through NF-κB and MAPK signaling. TNF, synthesized as a membrane-bound protein and released by proteolytic cleavage, acts via TNFR1 and TNFR2 to amplify inflammatory gene expression and mediate tissue damage. Additional contributors to PFS pathogenesis include endoplasmic reticulum aminopeptidase 2 (ERAP2), which influences antigen processing and presentation to immune cells, and IKAROS family zinc finger 1 (IKZF1), a transcription factor crucial for lymphocyte development and immune regulation. Aberrant function or genetic variation in these molecules can promote inappropriate immune activation and recurrent inflammatory episodes characteristic of PFS. Therapeutically, targeting these molecules has shown significant promise. IL1B and TNF inhibitors, such as anakinra, canakinumab, and etanercept, have demonstrated efficacy in reducing fever frequency and severity in various PFS subtypes, validating these cytokines as actionable targets. ERAP2 and IKZF1, while less established in clinical practice, represent emerging targets for modulating immune responses and disease susceptibility. Ongoing research aims to develop small molecule modulators and biologics that can fine-tune these pathways, supporting personalized treatment approaches. Moreover, these targets serve as valuable biomarkers for diagnosis, disease monitoring, and predicting therapeutic response, advancing precision medicine in autoinflammatory syndromes.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates drug discovery for Periodic Fever Syndrome by providing advanced screening and characterization platforms. We offer a comprehensive suite of cell-based, biochemical, and biophysical assays targeting key inflammatory mediators including IL-1β, TNF, and ERAP2. Utilizing ELISA, chemiluminescence, fluorescence, SPR, and RNA assays, we assess drug potency, binding affinity, and minimal effective concentrations. Our service enables detailed evaluation of immune modulation, cytokine inhibition, and target engagement, delivering robust, reproducible data to guide compound optimization and selection for preclinical development in autoinflammatory disease research.

Albumin Checkpoint Kinase 1
Endoplasmic Reticulum Aminopeptidase 2 Interleukin 1 Beta
Tumor Necrosis Factor

Learn More

Why Choose Us

Choosing Protheragen means partnering with a team deeply committed to advancing therapeutics for Periodic fever syndrome (autoinflammatory syndrome). Protheragen brings specialized expertise in the research and development of new drugs targeting autoinflammatory conditions, ensuring that each project benefits from the latest scientific knowledge and clinical insights. Our professional teams are equipped with advanced technology platforms, enabling precise and efficient preclinical studies tailored to the unique challenges of Periodic fever syndrome. With a proven track record in preclinical drug development, Protheragen has established itself as a reliable partner for pharmaceutical innovation, consistently delivering high-quality results. We adhere strictly to rigorous quality standards and maintain full regulatory compliance throughout every stage of development, providing our partners with confidence and peace of mind. At Protheragen, we are dedicated to making a meaningful impact in the field of autoinflammatory diseases by accelerating the discovery and development of effective new therapeutics for Periodic fever syndrome. Our unwavering commitment to excellence and innovation ensures that your project is in the best possible hands.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Periodic fever syndrome (autoinflammatory syndrome)?

A: One of the primary challenges in preclinical research for Periodic fever syndrome (PFS) is the limited availability of robust animal models that accurately recapitulate the human disease phenotype. Additionally, the heterogeneity of genetic mutations and clinical presentations in PFS complicates the selection of relevant biomarkers and endpoints. Our company addresses these challenges by leveraging advanced genetic engineering technologies to develop customized animal models and by utilizing multi-omics approaches to identify and validate translational biomarkers.

Q: What are the key regulatory considerations in the preclinical development of drugs for Periodic fever syndrome (autoinflammatory syndrome)?

A: Given the rarity and complexity of PFS, it is essential to engage early with regulatory agencies to align on acceptable preclinical models, endpoints, and safety requirements. Specific considerations include demonstrating proof-of-concept in relevant models, establishing a strong safety profile, and providing a clear rationale for dose selection. Our regulatory team is experienced in preparing pre-IND packages and facilitating scientific advice meetings with agencies such as the FDA and EMA to ensure a streamlined path to clinical development.

Q: What technical aspects are critical in preclinical research for Periodic fever syndrome (autoinflammatory syndrome)?

A: Critical technical aspects include the selection and validation of disease-relevant in vitro and in vivo models, the development of sensitive assays to measure inflammatory markers (e.g., IL-1β, TNF-α), and the use of advanced imaging and molecular profiling techniques to monitor disease progression and treatment response. Our laboratories are equipped with state-of-the-art technology for cytokine profiling, genetic analysis, and bioimaging, enabling comprehensive characterization of drug candidates.

Q: What is the typical timeline and cost for preclinical development of a new drug targeting Periodic fever syndrome (autoinflammatory syndrome)?

A: Preclinical development timelines for PFS drugs can vary depending on the complexity of the candidate and the need for specialized models, but generally range from 18 to 36 months. Costs typically fall within the range of $2 million to $6 million, encompassing model development, pharmacology, toxicology, and regulatory documentation. Our project management team works closely with clients to optimize study designs and timelines, ensuring cost-effective and timely execution.

Q: What are the key success factors in preclinical drug development for Periodic fever syndrome (autoinflammatory syndrome)?

A: Key success factors include the use of well-characterized and disease-relevant models, early identification of predictive biomarkers, robust safety and efficacy data, and proactive regulatory engagement. Our integrated approach combines scientific expertise, cutting-edge technology, and regulatory know-how to maximize the likelihood of successful transition from preclinical to clinical development for PFS drug candidates.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.